Deutsche Bank Downgrades Apogee Therapeutics to Hold, Raises Price Target to $135

Benzinga Newsdesk www.benzinga.com Negative 55.7%

Neg 55.7% Neu 0% Pos 0%

Deutsche Bank analyst David Hoang downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Hold and raises the price target from $116 to $135.